IMCR vs. TWST, DNLI, ACLX, IOVA, SWTX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Twist Bioscience (TWST), Denali Therapeutics (DNLI), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Immunocore (NASDAQ:IMCR) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Twist Bioscience received 41 more outperform votes than Immunocore when rated by MarketBeat users. However, 70.59% of users gave Immunocore an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Immunocore has a net margin of -22.60% compared to Twist Bioscience's net margin of -69.24%. Immunocore's return on equity of -16.54% beat Twist Bioscience's return on equity.
Immunocore currently has a consensus target price of $81.85, indicating a potential upside of 53.59%. Twist Bioscience has a consensus target price of $42.50, indicating a potential downside of 9.59%. Given Immunocore's higher probable upside, research analysts plainly believe Immunocore is more favorable than Twist Bioscience.
In the previous week, Immunocore had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 20 mentions for Immunocore and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.74 beat Immunocore's score of 0.13 indicating that Twist Bioscience is being referred to more favorably in the news media.
84.5% of Immunocore shares are owned by institutional investors. 9.1% of Immunocore shares are owned by insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immunocore has higher earnings, but lower revenue than Twist Bioscience. Immunocore is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Immunocore has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
Summary
Immunocore beats Twist Bioscience on 12 of the 18 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
